Kyverna Therapeutics (NASDAQ:KYTX) Stock Price Down 6.7% – Here’s Why

Kyverna Therapeutics, Inc. (NASDAQ:KYTX)’s share price traded down 6.7% on Friday . The stock traded as low as $8.93 and last traded at $8.9390. 304,427 shares changed hands during trading, a decline of 59% from the average session volume of 742,747 shares. The stock had previously closed at $9.58.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Finally, Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.67.

Kyverna Therapeutics Stock Down 6.6%

The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.75 and a current ratio of 7.75. The stock has a market capitalization of $540.94 million, a price-to-earnings ratio of -2.45 and a beta of 2.62. The firm’s fifty day simple moving average is $8.26 and its 200 day simple moving average is $7.89.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). On average, sell-side analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Institutional Trading of Kyverna Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its holdings in Kyverna Therapeutics by 16.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after buying an additional 250,418 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Kyverna Therapeutics during the 4th quarter worth approximately $15,667,000. AIGH Capital Management LLC acquired a new stake in Kyverna Therapeutics during the 4th quarter worth approximately $14,100,000. Vanguard Group Inc. raised its holdings in Kyverna Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after buying an additional 9,858 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Kyverna Therapeutics during the 4th quarter worth approximately $9,220,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.